Most Read Articles
Roshini Claire Anthony, 6 days ago

The addition of the glucagon-like peptide-1 analogue semaglutide to standard of care resulted in sustained reduction in weight and waist circumference in individuals with type 2 diabetes (T2D) with high cardiovascular risk, according to the phase III SUSTAIN 6* trial presented at EASD 2017.

Yesterday
Overall survival (OS) and head and neck cancer (HNC)-specific survival vary among HNC sites, according to a study. In particular, cigarette smoking is a prognostic factor of OS and HNC-specific survival in patients with cancer of the oral cavity and oropharynx, whereas alcohol consumption is a prognostic factor of both survival outcomes in patients with cancer of the larynx.
18 Sep 2017
The additional use of intermittent low-energy diet (LED) or daily meal replacements after a mean 10-percent weight loss and 1-year maintenance effectively maintains weight loss in obese patients with knee osteoarthritis for 3 years, according to a recent study.
2 days ago
Adiponectin, but not leptin, is significantly correlated with proteinuria and its severity in systemic lupus erythematosus (SLE) nephritis, reveals a new cross-sectional study.

Statin therapy linked to attenuation of tocilizumab-associated lipid increase

Pearl Toh
21 Jan 2017

Concomitant statin therapy was associated with an attenuation of tocilizumab (TCZ)-mediated increase in serum lipids in patients with rheumatoid arthritis (RA), according to a recent post hoc analysis of randomized clinical studies.

“Treatment with TCZ has been shown to increase lipid levels,” said the researchers, noting that RA patients have higher cardiovascular (CV) risk and lower survival than the general population. “LDL-C [low-density lipoprotein cholesterol] levels should be monitored and managed in patients with RA.”  

The retrospective post hoc analysis included seven double-blind randomized controlled phase III and IV clinical trials involving a total of 4,655 patients with moderate to severe active RA who were treated with ≥1 dose of TCZ (either intravenously [IV] or subcutaneously [SC] as monotherapy, or in combination with conventional synthetic disease-modifying antirheumatic drugs [csDMARDs]). [Rheumatol Ther 2016;doi:10.1007/s40744-016-0049-8]

A proportion of patients (n=443, 9.5 percent) were already receiving concomitant statins at baseline and 5.9 percent (n=264) initiated statins during the study, while the majority of the patients (84.8 percent, n=3,948) never started on the drug during the study period.   

Among patients who were receiving concomitant statin at baseline, a smaller proportion saw their LDL-C levels increased from <130 mg/dL at baseline to ≥130 mg/dL over the first 3–4 months of TCZ therapy (31.8, 24.8, and 29.8 percent for TCZ-IV, TCZ-IV plus csDMARDs, and TCZ-SC, respectively), compared with those who never used statins during the study (38.4, 36.7, and 42.4 percent for TCZ-IV, TCZ-IV plus csDMARDs, and TCZ-SC, respectively) or those who initiated statins during the study period (53.3, 73.3, and 64.7 percent for TCZ-IV, TCZ-IV plus csDMARDs, and TCZ-SC, respectively).

From 3–4 months onwards, LDL-C levels remained high in TCZ-treated patients who were also on concomitant statins at baseline or who never used statins, while LDL-C levels gradually decreased among those who started on statins during the study, indicating a trend toward normalization of high lipid levels.       

Similar trends were also observed for HDL-C, total cholesterol, and triglycerides.

At 2 years, the researchers found that less than 15 percent of patients with LDL-C ≥100 mg/dL and less than 35 percent of patients with a total cholesterol:HDL-C ratio >5 were treated with statins despite the potential CV risk.

“Unfortunately, many current risk calculators may underestimate CV disease risk in patients with RA, indicating a need for an RA-specific calculator to estimate risk of CV disease,” according to the researchers, who noted that many of the CV risk calculators such as the Framingham Risk Score and the Systematic Coronary Risk Evaluation, do not account for additional RA-specific risks as they are developed for the general population.

The European League Against Rheumatism guidelines recommended that “risk-score models should be adapted for patients with RA by introducing a 1.5x multiplication factor, and this multiplication factor should be used when patients with RA meet two of the following three criteria: disease duration >10 years, rheumatoid factor or anticyclic citrullinated peptide antibody positivity, and/or presence of certain extra-articular manifestations”, the researchers added. [Ann Rheum Dis 2010;69:325-331]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 6 days ago

The addition of the glucagon-like peptide-1 analogue semaglutide to standard of care resulted in sustained reduction in weight and waist circumference in individuals with type 2 diabetes (T2D) with high cardiovascular risk, according to the phase III SUSTAIN 6* trial presented at EASD 2017.

Yesterday
Overall survival (OS) and head and neck cancer (HNC)-specific survival vary among HNC sites, according to a study. In particular, cigarette smoking is a prognostic factor of OS and HNC-specific survival in patients with cancer of the oral cavity and oropharynx, whereas alcohol consumption is a prognostic factor of both survival outcomes in patients with cancer of the larynx.
18 Sep 2017
The additional use of intermittent low-energy diet (LED) or daily meal replacements after a mean 10-percent weight loss and 1-year maintenance effectively maintains weight loss in obese patients with knee osteoarthritis for 3 years, according to a recent study.
2 days ago
Adiponectin, but not leptin, is significantly correlated with proteinuria and its severity in systemic lupus erythematosus (SLE) nephritis, reveals a new cross-sectional study.